von Pawel, J., Spigel, D. R., Ervin, T., Losonczy, G., Barlesi, F., Juhász, E., . . . Reck, M. (2018). Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer. The oncologist (Dayton, Ohio), 23(6), 654-e58. https://doi.org/10.1634/theoncologist.2017-0690
Citace podle Chicago (17th ed.)von Pawel, Joachim, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer." The Oncologist (Dayton, Ohio) 23, no. 6 (2018): 654-e58. https://doi.org/10.1634/theoncologist.2017-0690.
Citace podle MLA (9th ed.)von Pawel, Joachim, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer." The Oncologist (Dayton, Ohio), vol. 23, no. 6, 2018, pp. 654-e58, https://doi.org/10.1634/theoncologist.2017-0690.